LXRX News and Press, Lexicon Pharmaceuticals Inc. From 01/15/21

After more than doubling in value on Thursday, shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) are giving up some of those gains on Friday. The company's stock was down by 13.7% as of 12:39 p.m. EST today, after dropping by as much as 18.6% earlier in the day. The company did n...

Gainers: Ceragon Networks (CRNT) +67%.ObsEva (OBSV) +60%.Polar Power (POLA) +50%.Charah Solutions (CHRA) +46%.Avinger (AVGR) +45%.DBV Technologies (DBVT) +42%.Novan (NOVN) +42%.Senseonics (SENS) +42%.Atlantic Power (AT) +40%.Driven Brands (DRVN) +31%.Losers: Dogness (DOGZ)...

Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%,&...

Now this is a stock pop. On Thursday, shares of Lexicon Pharmaceutials (NASDAQ: LXRX) jumped 105% (no, that's not a typo) after the company issued a major positive regulatory update. The happy news is that Lexicon's clinical-stage protein inhibitor sotagliflozin performed we...

Citi analyst Yigai Nochomovitz raises the price target on Lexicon Pharmaceuticals (LXRX) to a Street high $13 from previous $7 PT and maintains Buy rating.LXRX stock doubled in regular trading on Thursday to close at $8.05 after the company cleared a key hurdle for partnership discussions reg...

Gainers: Datasea (DTSS) +90%.Lexicon Pharmaceuticals (LXRX) +85%.Pennsylvania Real Estate Investment Trust (PEI) +50%.DPW Holdings (DPW) +36%.Organogenesis (ORGO) +34%.Acacia Communications (ACIA) +33%.Bicycle Therapeutics (BCYC) +31%.AeroVironment (AVAV) +29%.Maxar Technologie...

Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx N.V. (IFRX) -9...

Lexicon Pharmaceuticals (LXRX) is trading ~11.0% higher in premarket trading after announcing positive regulatory feedback for two of its late-stage trials that evaluated the cardiovascular efficacy of sotagliflozin, an oral dual inhibitor of two proteins accountable for g...

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new dru...

Biotech Penny Stocks to Watch Friday, January 8th was a relatively good day for many penny stocks . After a week of volatility in the stock market, Friday represented a relatively calm day for investors. Now that the year is off to a decent start, there are a few catalysts that rema...